SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate the impact of Warren Buffett's transition away from active leadership and the company's decision to maintain record cash reserves rather than deploying capital into the current market rally. Community discussion centers on frustration over stagnant performance compared to broader indices, with many investors actively questioning the future direction of the conglomerate under CEO Greg Abel.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as members of the community point to recent Google research papers highlighting the protocol's post-quantum cryptography features as a potential long-term catalyst. While some investors remain cautious due to historical price performance, others are actively discussing institutional adoption narratives and technical developments as reasons to continue building their positions.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as the community reacts to the announced preliminary design for the Phase 3 clinical trial of its lead candidate, CAD-1005, for Heparin-Induced Thrombocytopenia. Investors are actively debating the company's long-term clinical prospects versus concerns regarding ongoing cash burn and the potential for future equity offerings.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending following a strong quarterly earnings report that featured an EPS beat and raised full-year guidance, driven by significant momentum in its platform and advertising business. Investors and community members are actively debating the stock's long-term valuation and potential for further institutional upgrades, as the company reaches a milestone of 100 million streaming households.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is facing intense bearish sentiment and significant volatility, with community members expressing deep frustration over its weak performance compared to Bitcoin and other assets. While some traders view the current price drop as a long-term accumulation opportunity for RWA tokenization, others are actively panic-selling and calling for a broader crypto market exit amid fears of a deeper downturn.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors debate whether the stock is a legitimate play on the critical indium phosphide supply chain bottleneck for AI infrastructure or an overvalued Chinese-led pump-and-dump scheme. Community discussion is polarized, with some highlighting high institutional interest and potential for parabolic gains, while critics point to massive insider selling, negative earnings, and concerns over significant upcoming share dilution.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending as investors focus on the potential of its lead asset, soquelitinib, following positive analyst price target initiations and anticipation surrounding upcoming data readouts. The community remains deeply divided, with bulls highlighting the drug's oral delivery and unique mechanism as a buyout candidate, while bears point to the stock's recent volatility and the risks inherent in early-stage clinical trials.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh the stock's long-term growth potential against market volatility driven by regional geopolitical tensions and evolving natural gas supply constraints. The community is actively debating whether the current price represents a buying opportunity ahead of upcoming earnings or if it will continue to trade in a range bound by persistent rumors regarding regional stability.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is drawing significant community attention as it navigates a complex retail landscape, balancing news of its nationwide digital price tag rollout with mixed sentiment regarding its current valuation multiples. Investors are actively debating whether its status as a defensive 'safe haven' remains justified given rising operational pressures and ongoing insider activity.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending following its Q4 2025 earnings report, which highlighted strong IBSRELA revenue growth and increased 2026 operating expenses, dividing community opinion while insider buying and a new LPGA partnership add to the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jennison Associates LLC Reduces Holdings in Apellis Pharmaceuticals, Inc. $APLS

Jennison Associates LLC cut its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 65.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,504,299 shares of the company's stock after selling 2,843...

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Q1 Earnings Call Highlights

Biogen (NASDAQ:BIIB) executives pointed to a very strong start to 2026, highlighting growth in key products, progress across the late-stage pipeline, and preparations for the pending acquisition of...

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?

Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Wednesday

Apellis Pharmaceuticals (NASDAQ:APLS) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Cwm LLC Sells 52,353 Shares of Apellis Pharmaceuticals, Inc. $APLS

Cwm LLC trimmed its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 55.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the...

Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 1-Year High - What's Next?

Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 12-Month High - Here's Why...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling...

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?

Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

APLS
Apellis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest APLS News

APLSApellis Pharmaceuticals Inc